Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MEDS Stock Summary
Top 10 Correlated ETFs
MEDS
In the News
Why Is Trxade Health (MEDS) Stock Up 230% Today?
Trxade Health (NASDAQ: MEDS ) stock is soaring higher on Tuesday after the U.S. health services IT company announced a major asset sale. According to a filing with the Securities and Exchange Commission (SEC), wholly-owned subsidiary Trxade, Inc. is going to sell virtually all of its assets to Micro Merchant Systems.
TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.
TAMPA, FL / ACCESSWIRE / July 31, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the second quarter 2023, after market close on August 14, 2023.
Why Is Trxade Health (MEDS) Stock Down 13% Today?
Trxade Health (NASDAQ: MEDS ) stock is falling on Tuesday after the company announced it would undergo a merger with Superlatus . That merger will see Trxade Health distribute 3,839,176 shares of MEDS stock to current shareholders in Superlatus.
TRxADE Health (MEDS) Stock Soars 60% on Reverse Split
One of the biggest movers in today's market is little-known health tech company TRxADE Health (NASDAQ: MEDS ). Shares of MEDS stock have rocketed more than 60% higher as of this writing on an otherwise uneventful day in the market.
TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript
TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q1 2023 Earnings Conference Call May 15, 2023 6:00 PM ET Company Participants Prashant Patel - Interim Chief Financial Officer Suren Ajjarapu - Founder, Chairman and Chief Executive Officer Conference Call Participants Allen Klee - Maxim Group LLC Howard Halpern - Taglich Brothers, LLC Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
TRxADE (MEDS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.12 per share a year ago.
TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.
TAMPA, FL / ACCESSWIRE / May 5, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 15, 2023.
TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.
TAMPA, FL / ACCESSWIRE / April 25, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 8, 2023.
TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript
TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q4 2022 Earnings Conference Call March 27, 2023 5:30 PM ET Company Participants Prashant Patel - CFO Surendra Ajjarapu - Founder, Chairman and CEO Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates
TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MEDS Financial details
MEDS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.66 | 1.25 | 2.22 | 1.22 | 1.35 | |
Net income per share | 0 | -0.07 | -0.33 | -0.51 | -0.51 | |
Operating cash flow per share | 0.05 | 0.02 | -0.29 | -0.32 | -0.18 | |
Free cash flow per share | 0.04 | 0.01 | -0.29 | -0.32 | -0.23 | |
Cash per share | 0.15 | 0.48 | 0.77 | 0.38 | 0.13 | |
Book value per share | 0.15 | 0.7 | 1.13 | 0.46 | 0.09 | |
Tangible book value per share | 0.02 | 0.58 | 1.13 | 0.46 | -0.01 | |
Share holders equity per share | 0.15 | 0.7 | 1.13 | 0.46 | 0.09 | |
Interest debt per share | 0.15 | 0.18 | 0.09 | 0.16 | 0.23 | |
Market cap | 26.21M | 97.83M | 611.44M | 288.04M | 51.26M | |
Enterprise value | 26.19M | 95.96M | 606.15M | 286.17M | 51.71M | |
P/E ratio | 2.9K | -238.77 | -238.34 | -70.03 | -11.89 | |
Price to sales ratio | 6.84 | 13.16 | 35.71 | 29.13 | 4.48 | |
POCF ratio | 95.89 | 690.04 | -276.07 | -112.24 | -33.59 | |
PFCF ratio | 101.45 | 1.64K | -271.48 | -111.26 | -25.93 | |
P/B Ratio | 31.03 | 23.63 | 70.45 | 76.4 | 67.17 | |
PTB ratio | 31.03 | 23.63 | 70.45 | 76.4 | 67.17 | |
EV to sales | 6.83 | 12.9 | 35.4 | 28.94 | 4.52 | |
Enterprise value over EBITDA | 107.39 | 145.27 | -361.2 | -55.53 | -20.36 | |
EV to operating cash flow | 95.79 | 676.82 | -273.68 | -111.51 | -33.89 | |
EV to free cash flow | 101.36 | 1.61K | -269.13 | -110.54 | -26.16 | |
Earnings yield | 0 | 0 | 0 | -0.01 | -0.08 | |
Free cash flow yield | 0.01 | 0 | 0 | -0.01 | -0.04 | |
Debt to equity | 1 | 0.24 | 0.07 | 0.33 | 2.08 | |
Debt to assets | 0.38 | 0.18 | 0.06 | 0.22 | 0.43 | |
Net debt to EBITDA | -0.1 | -2.84 | 3.15 | 0.36 | -0.18 | |
Current ratio | 1.7 | 7.3 | 10.95 | 4.72 | 0.98 | |
Interest coverage | -1.52 | 10.63 | -60.59 | -224.34 | -8.2 | |
Income quality | 30.25 | -0.5 | 0.87 | 0.48 | 0.39 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.61 | 0.59 | 0.44 | 0.89 | 0.62 | |
Research and developement to revenue | 0.25 | 0.09 | 0.04 | 0.14 | 0.1 | |
Intangibles to total assets | 0.33 | 0.13 | 0 | 0 | 0.12 | |
Capex to operating cash flow | -0.05 | -0.58 | 0.02 | 0.01 | 0.3 | |
Capex to revenue | 0 | -0.01 | 0 | 0 | -0.04 | |
Capex to depreciation | 0 | -0.87 | -0.37 | -0.16 | -2.3 | |
Stock based compensation to revenue | 0 | 0.04 | 0.11 | 0.04 | 0.03 | |
Graham number | 0.07 | 1.04 | 2.9 | 2.3 | 1.02 | |
ROIC | -0.94 | 0.14 | -0.19 | -0.65 | -0.89 | |
Return on tangible assets | 0.01 | -0.08 | -0.26 | -0.71 | -1.32 | |
Graham Net | -0.03 | 0.35 | 0.89 | 0.23 | -0.19 | |
Working capital | 605.71K | 3.28M | 8.38M | 3.45M | -53.67K | |
Tangible asset value | 118.7K | 3.41M | 8.68M | 3.77M | -107.98K | |
Net current asset value | 83.16K | 2.37M | 8.11M | 2.38M | -1.27M | |
Invested capital | 1 | 0.24 | 0.07 | 0.33 | 2.08 | |
Average receivables | 376.55K | 612.84K | 1.34M | 1.44M | 853.97K | |
Average payables | 253.31K | 367.58K | 295.72K | 366.93K | 603.09K | |
Average inventory | 91.03K | 68.36K | 657.26K | 657.02K | 87.93K | |
Days sales outstanding | 41.31 | 38.88 | 40.35 | 36.13 | 23.24 | |
Days payables outstanding | 325.57 | 47.61 | 8.21 | 33.85 | 44.38 | |
Days of inventory on hand | 65 | 8.08 | 40.22 | 3.99 | 7.28 | |
Receivables turnover | 8.84 | 9.39 | 9.05 | 10.1 | 15.7 | |
Payables turnover | 1.12 | 7.67 | 44.45 | 10.78 | 8.22 | |
Inventory turnover | 5.62 | 45.2 | 9.08 | 91.39 | 50.15 | |
ROE | 0.01 | -0.1 | -0.3 | -1.09 | -5.65 | |
Capex per share | 0 | -0.01 | 0 | 0 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.29 | 0.3 | 0.22 | 3.3 | 0.87 | |
Net income per share | -0.06 | -0.21 | -0.01 | -2.9 | -1.49 | |
Operating cash flow per share | -0.07 | 0.15 | -0.09 | 0.48 | -0.26 | |
Free cash flow per share | -0.08 | 0.13 | -0.1 | 0.41 | -0.26 | |
Cash per share | 0.04 | 0.13 | 0.12 | 1.09 | 0.01 | |
Book value per share | 0.17 | 0.09 | 0.07 | -1.9 | 4.89 | |
Tangible book value per share | 0.03 | -0.01 | 0.01 | -2.77 | -1.28 | |
Share holders equity per share | 0.17 | 0.09 | 0.07 | -1.9 | 4.89 | |
Interest debt per share | 0.21 | 0.21 | 0.11 | 1.72 | 2.85 | |
Market cap | 139.83M | 51.26M | 44.57M | 8.89M | 16.61M | |
Enterprise value | 141.14M | 51.71M | 44.41M | 9.13M | 23.06M | |
P/E ratio | -69.5 | -7.25 | -178.58 | -1.13 | -1.18 | |
Price to sales ratio | 58.26 | 20.27 | 19.83 | 3.95 | 8.07 | |
POCF ratio | -242.37 | 41.67 | -47.84 | 27.06 | -27.55 | |
PFCF ratio | -221.02 | 45.97 | -43.76 | 32.12 | -27.55 | |
P/B Ratio | 99.95 | 67.17 | 68.03 | -6.87 | 1.44 | |
PTB ratio | 99.95 | 67.17 | 68.03 | -6.87 | 1.44 | |
EV to sales | 58.8 | 20.45 | 19.76 | 4.06 | 11.21 | |
Enterprise value over EBITDA | -354.05 | -212.41 | -152.68 | -31.26 | -37.4 | |
EV to operating cash flow | -244.64 | 42.04 | -47.68 | 27.79 | -38.24 | |
EV to free cash flow | -223.09 | 46.37 | -43.6 | 33 | -38.24 | |
Earnings yield | 0 | -0.03 | 0 | -0.22 | -0.21 | |
Free cash flow yield | 0 | 0.02 | -0.02 | 0.03 | -0.04 | |
Debt to equity | 1.16 | 2.08 | 1.58 | -0.76 | 0.56 | |
Debt to assets | 0.35 | 0.43 | 0.26 | 0.26 | 0.3 | |
Net debt to EBITDA | -3.28 | -1.85 | 0.54 | -0.83 | -10.46 | |
Current ratio | 1.15 | 0.98 | 0.94 | 0.49 | 0.61 | |
Interest coverage | -3.13 | -1.42 | -5.57 | -1.91 | -3.36 | |
Income quality | 1.09 | -0.94 | 1.37 | -0.17 | -0.93 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.63 | 0.59 | 0.74 | 0.69 | 1.04 | |
Research and developement to revenue | 0.12 | 0.13 | 0.1 | 0.2 | 0.2 | |
Intangibles to total assets | 0.23 | 0.12 | 0.13 | 0.16 | 0.67 | |
Capex to operating cash flow | 0.1 | -0.09 | 0.09 | -0.16 | 0 | |
Capex to revenue | -0.02 | -0.05 | -0.04 | -0.02 | 0 | |
Capex to depreciation | -0.86 | -5.27 | -1.66 | -0.97 | 0 | |
Stock based compensation to revenue | 0.01 | -0.02 | 0.03 | 0.01 | 0.3 | |
Graham number | 0.48 | 0.65 | 0.1 | 11.13 | 12.81 | |
ROIC | -0.09 | -0.11 | -0.02 | -0.55 | -0.97 | |
Return on tangible assets | -0.14 | -0.54 | -0.02 | -0.63 | -0.5 | |
Graham Net | -0.2 | -0.19 | -0.16 | -5.3 | -2.91 | |
Working capital | 311.65K | -53.67K | -164.04K | -2.17M | -3.54M | |
Tangible asset value | 257.58K | -107.98K | 117.22K | -1.88M | -3.02M | |
Net current asset value | -959.68K | -1.27M | -996.52K | -2.94M | -4.55M | |
Invested capital | 1.16 | 2.08 | 1.58 | -0.76 | 0.56 | |
Average receivables | 1.37M | 1.23M | 718.44K | 753.68K | 1.52M | |
Average payables | 969.8K | 736.78K | 622.46K | 689.67K | 1.1M | |
Average inventory | 101.54K | 97.77K | 122.92K | 143.76K | 1.59M | |
Days sales outstanding | 64.7 | 25.94 | 28.34 | 31.96 | 97.99 | |
Days payables outstanding | 67.11 | 66.53 | 67.21 | 128.18 | 338.31 | |
Days of inventory on hand | 6.85 | 10.91 | 16.45 | 23.94 | 770.75 | |
Receivables turnover | 1.39 | 3.47 | 3.18 | 2.82 | 0.92 | |
Payables turnover | 1.34 | 1.35 | 1.34 | 0.7 | 0.27 | |
Inventory turnover | 13.14 | 8.25 | 5.47 | 3.76 | 0.12 | |
ROE | -0.36 | -2.32 | -0.1 | 1.53 | -0.3 | |
Capex per share | -0.01 | -0.01 | -0.01 | -0.08 | 0 |
MEDS Frequently Asked Questions
What is TRxADE HEALTH, Inc. stock symbol ?
TRxADE HEALTH, Inc. is a US stock , located in Land o'lakes of Fl and trading under the symbol MEDS
What is TRxADE HEALTH, Inc. stock quote today ?
TRxADE HEALTH, Inc. stock price is $10.17 today.
Is TRxADE HEALTH, Inc. stock public?
Yes, TRxADE HEALTH, Inc. is a publicly traded company.